Nubeqa is a nonsteroidal second-generation androgen receptor inhibitor that competes with androgen by binding to the androgen receptor. It reduces the ability of androgen to promote the growth of prostate cancer cells. Nubeqa is indicated for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

If you have a Hayes login, click here to view the full report on the Knowledge Center.